Compare IDEXX Laboratories, Inc. (IDXX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Johnson Controls International PLC — how do they compare? IDEXX Laboratories, Inc. trades at $551.53 (market cap $44.48B), while Johnson Controls International PLC trades at $142.41 (market cap $85.03B). The key difference: Johnson Controls International PLC is the larger of the two by market cap, and Johnson Controls International PLC pays a 1.15% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | JCI | |
|---|---|---|
Market Cap | $44.48B | $85.03B |
Sector | Health | Industrials |
52-Week High | $766.68 | $148.21 |
52-Week Low | $520.87 | $103.24 |
Enterprise Value | $45.38B | $93.86B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Johnson Controls (JCI) trades at $139.03, down 1.02% today, with technical indicators showing bearish momentum despite strong analyst support. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.19 versus $1.12, maintaining a pattern of earnings outperformance. Recent corporate developments include a $0.40 dividend declaration and board appointments, while cash flow trends show improvement with projected positive net cash flow of $157M for 2026.
JCI presents a compelling investment case with 62% analyst buy ratings and a $158.29 consensus price target offering 14% upside. However, elevated valuation multiples (P/E 42.95, EV/EBITDA 26.89) and bearish technical signals warrant caution. Key risks include competitive pressures in building technologies and sensitivity to commercial construction cycles, balanced by strong profitability margins and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
